NasdaqCM - Nasdaq Real Time Price USD

Rezolute, Inc. (RZLT)

3.9600

+0.2000

+(5.32%)

At close: May 1 at 4:00:00 PM EDT

Rezolute to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism, today announced that management will participate in the following investor conferences: Event: The Citizens JMP Life Sciences Conference Date: May 7-8, 2025 Event: H.C. Wainwright BioConnect Investor Conference Date: May 20, 2025 Event: Craig-Ha

GlobeNewswire 22 hours ago

RZLT
+5.32%
Rezolute, Inc. Announces Closing of Underwritten Offering

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the closing of its previously announced underwritten offering (the “Offering”) of an aggregate of 24,940,769 shares of its common stock at an offering price of $3.25 per share, which includes 4,153,846 shares of common stock pursuant to the exercise in ful

GlobeNewswire 6 days ago

RZLT
+5.32%
Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the pricing of an underwritten offering, priced at-the-market under Nasdaq rules, of an aggregate of 20,786,923 shares of its common stock at an offering price of $3.25 per share, and, to certain investors in lieu of common stock, pre-funded warrants to pu

GlobeNewswire 8 days ago

RZLT
+5.32%
Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”)

Independent Data Monitoring Committee (the “DMC”) recommends continuation of sunRIZE trial as planned with no need to increase sample size Enrollment on track and expected to be completed in May 2025; topline data anticipated in December 2025 U.S. sites activated and enrolling patients REDWOOD CITY, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (the “Company or “Rezolute”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare

GlobeNewswire 8 days ago

RZLT
+5.32%
Is Rezolute (NASDAQ:RZLT) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 9 days ago

RZLT
+5.32%
Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, announced the appointment of Erik Harris to its Board of Directors, effective immediately. Mr. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx, brings more than 20 years of biopharmaceutical expertise to Rezolute. “We are thrill

GlobeNewswire last month

RZLT
+5.32%
Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), receives Breakthrough Therapy Designation and Orphan Drug Designation Open-label arm (infant participants < 1 year old) of the sunRIZE study has been reviewed by a Data Monitoring Committee (DMC); target drug concentrations were safely reached at tested doses and infants are approved for enrollment into the double-blind portion of the study REDWOOD CITY, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Rezolu

GlobeNewswire 2 months ago

RZLT
+5.32%
Rezolute Insiders Placed Bullish Bets Worth US$557.5k

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...

Simply Wall St. 2 months ago

RZLT
+5.32%
Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Open-label arm (infant participants < 1 year old) has been recently reviewed by a Data Monitoring Committee (DMC) and target drug concentrations were safely reached at tested doses DMC approved enrollment of infants into the double-blind portion of the study sunRIZE enrollment completion expected in Q2 2025, subject to outcomes from upcoming interim analysis REDWOOD CITY, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharma

GlobeNewswire 2 months ago

RZLT
+5.32%
Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference

REDWOOD CITY, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, today announced that management will participate in the Guggenheim SMID Cap Biotech Conference, taking place February 5-6, 2025, in New York City. Management will be participating in one-on-one investor meetings throughout the conference. Investors in

GlobeNewswire 2 months ago

RZLT
+5.32%
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Breakthrough Therapy Designation granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism (HI) Ersodetug continues to advance in clinical development as a potential treatment for hypoglycemia caused by all forms of hyperinsulinism; topline sunRIZE data expected second half of this year REDWOOD CITY, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceut

GlobeNewswire 3 months ago

RZLT
+5.32%
Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, today announced that its compensation committee has approved the issuance of One Hundred and Fifty Thousand (150,000) shares of its common stock as an inducement award (the “Inducement Award”) permitted under Nasdaq Rule 5635(c)(4) to its new Senior V

GlobeNewswire 4 months ago

RZLT
+5.32%
FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Phase 3 registrational trial for ersodetug in patients with tumor hyperinsulinism (HI) expected to commence in 2025; real-world patient benefit demonstrated in Expanded Access ProgramREDWOOD CITY, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, today announced the U.S. Food and Drug Administration (FDA) has gran

GlobeNewswire 4 months ago

RZLT
+5.32%
We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, Rezolute ( NASDAQ:RZLT...

Simply Wall St. 5 months ago

RZLT
+5.32%
Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), advancing in two late-stage, registrational clinical trials in two indications Phase 3 sunRIZE study on track; U.S. enrollment expected to commence in the first part of 2025 Phase 3 tumor HI study expected to commence in the first half of 2025 REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedic

GlobeNewswire 5 months ago

RZLT
+5.32%
With 62% ownership, Rezolute, Inc. (NASDAQ:RZLT) boasts of strong institutional backing

Key Insights Significantly high institutional ownership implies Rezolute's stock price is sensitive to their trading...

Simply Wall St. 6 months ago

RZLT
+5.32%
Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update

FDA lifts partial clinical holds on ersodetug for the treatment of congenital HI; Phase 3 sunRIZE study to proceed in the U.S. Phase 3 study for ersodetug for the treatment of tumor HI expected to commence in the first half of 2025 REDWOOD CITY, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, today reported fin

GlobeNewswire 7 months ago

RZLT
+5.32%
FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study

Commencing study startup activities in the U.S.; participant enrollment anticipated in early 2025REDWOOD CITY, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company developing a novel therapy to treat hyperinsulinism (HI), today announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical holds on RZ358 (ersodetug), a potential treatment for hypoglycemia caused by congenital HI. Ers

GlobeNewswire 7 months ago

RZLT
+5.32%
Pleasing Signs As A Number Of Insiders Buy Rezolute Stock

It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...

Simply Wall St. 7 months ago

RZLT
+5.32%
Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Second rare disease program with RZ358 in Phase 3 development Follows successful treatment of multiple patients with tumor hyperinsulinism under the Company’s Expanded Access Program REDWOOD CITY, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced that it received U.S. Food and Drug Administration (FDA) clear

GlobeNewswire 8 months ago

RZLT
+5.32%

Performance Overview

Return	RZLT	S&P 500 (^GSPC)
YTD	-19.18%	-4.72%
1-Year	+43.48%	+11.67%
3-Year	+4.21%	+35.63%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Rezolute, Inc. (RZLT)

Rezolute to Participate in Upcoming Investor Conferences

Rezolute, Inc. Announces Closing of Underwritten Offering

Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants

Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”)

Is Rezolute (NASDAQ:RZLT) In A Good Position To Deliver On Growth Plans?

Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

Rezolute Insiders Placed Bullish Bets Worth US$557.5k

Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully

Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

With 62% ownership, Rezolute, Inc. (NASDAQ:RZLT) boasts of strong institutional backing

Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update

FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study

Pleasing Signs As A Number Of Insiders Buy Rezolute Stock

Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Performance Overview